KCHF: Kyoto Congestive Heart Failure Study
Study Details
Study Description
Brief Summary
The purpose of this study is to investigate the patient characteristics, selection of treatment, and factors associated with clinical outcomes in Japanese patients with acutely decompensated congestive heart failure.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Congestive heart failure (CHF) has been markedly increasing in Japan due to the rapid aging of the society and the Westernization of lifestyle that facilitates the development of coronary artery disease. The prognosis of patients with CHF still remains poor, despite the recent advances in medical and surgical treatment. Elderly heart failure patients with preserved ejection and multiple comorbidity may account for significant portion among CHF patients in the real world clinical practice, however; most of previous prospective cohort studies excluded these patients. The KCHF registry, an all-comer, prospective, multicenter registry, was designed to investigate all patients who admitted to the hospital due to acutly decompensated CHF. The aim of this study was to clarify the patients characteristics , selection of treatment, and prognosis of patients with acutly decompensated CHF in the real-world clinical practice in Japan.
Study Design
Outcome Measures
Primary Outcome Measures
- hospital mortality [1-year]
Secondary Outcome Measures
- functional level at discharge measured by NYHA classification [1-year]
- improvement of dyspnea level at discharge measured by Likert scale [1-year]
- walking ability at discharge categorized by ambulatory, wheelchair (outdoor only), wheelchair (outdoor and indoor), bedridden [1-year]
- any severe ventricular arrhythmic event during hospitalization [1-year]
- onset of atrial fibrillation events during hospitalization [1-year]
- any bradyarrhythmic event during hospitalization [1-year]
- any stroke during hospitalization [1-year]
- any cardiac surgery during hospitalization [1-year]
- any cateter intervention during hospitalization [1-year]
- any device implantation during hospitalization [1-year]
- bleeding events during hospitalization (GUSTO definition; moderate to severe) [1-year]
- adverse drug events during hospitalization [1-year]
- infectious diseases during hospitalization [1-year]
- change of BNP at discharge (≧30% compared to BNP at admission ) [1-year]
- worsening renal function at discharge (raise of Cr≧0.3mg/dl compared to Cr at admission ) [1-year]
- usage of guideline recommended medicine during hospitalization [1-year]
- usage of tolvaptan during hospitalization [1-year]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
All patients who admitted to the participating centers due to acutly decompensated CHF defined by modified Framingham criteria
-
Patients who underwent heart failure treatment including intravenus drug
Exclusion Criteria:
- none
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Department of Cardiovascular Medicine, Kyoto University Hospital | Kyoto | Japan | 606-8507 |
Sponsors and Collaborators
- Kyoto University, Graduate School of Medicine
Investigators
- Principal Investigator: Takeshi Kimura, MD, PhD, Professor of Medicine, Department of Cardiovascular Medicine, Kyoto University Graduate School and Faculty of Medicine
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- E2311